Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19

doi:10.3390/vaccines9030243

Review

。2021 Mar11；9（3）：243。

doi:10.3390/vaccines9030243。

Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19

Carmen Elena Gómez^1个单击功能区上Beatriz Perdiguero^1个单击功能区上Mariano Esteban^1个

疲劳，疲劳

空气净化

^1个Centro Nacional de Biotecnología，Department of Molecular and Cellular Biology，Consejo Superior de Investigationes Científicas（CNB-CSIC），Campus de Cantoblanco，28049Madrid，Spain。

PMID: 33799505
PMCID: PMC7999234
DOI: 10.3390/vaccines9030243

Review

Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19

Carmen Elena Gómezet al。 Vaccines（Basel）。 2021。

。2021 Mar11；9（3）：243。

doi:10.3390/vaccines9030243。

Authors

Carmen Elena Gómez^1个单击功能区上Beatriz Perdiguero^1个单击功能区上Mariano Esteban^1个

空气净化

^1个Centro Nacional de Biotecnología，Department of Molecular and Cellular Biology，Consejo Superior de Investigationes Científicas（CNB-CSIC），Campus de Cantoblanco，28049Madrid，Spain。

PMID: 33799505
PMCID: PMC7999234
DOI: 10.3390/vaccines9030243

Abstract

The emergence of severe acute respiratory syndrome coronavirus-2（SARS-Cov-2）variants in different continents is causing a major concern in human global health。These variants have in common a high er transmissibility，becoming dominant within populations in a short time，and an accumulation of a high number of mutations in the spike（S）protein，especially within the amino terminal domain（NTD）and the receptor binding domain（RBD）。These mutations have direct implications on virus infection rates through higher affinity of S RBD for the cellular angiotensin-converting enzyme-2（ACE-2）receptor。There are also signs of enhanced virulence，re-infection frequency，and increased resistance to the action of monoclonal and polyclonal antibodies from convalescence sera and in vaccinated individuals in regions where the variants spread dominantly。In this review，we describe the different SARS-CoV-2variants that have thus far been identified in various parts of the world with mutational changes and biological properties as well astheir impact in medical countermeasures and human health。

Keywords:COVID-19；SARS-COV-2；lineage；mutation；neutralizing antibodies；spike protein；vaccine efficicacy；variant。

PubMed Disclaimer

整体安装

The authors declare no conflict of interest。

Cited by

Short-Term Adverse Effects of the Fourth Dose of Vaccination against COVID-19in Adults over40Years of Age。
Malo-Castillo J，Jiménez-Malvarez H，Ludeéa-Meléndez V，Mayor Castro SS，Rodríguez S，Ishikawa-Arias P，Terrones C，Ledesma Chavarría L，Linares Reyes E，Failoc-Rojas VE。 Malo-Castillo J，et al。 Vaccines（Basel）。2024Apr10；12（4）：400。doi:10.3390/vaccines12040400。 Vaccines（Basel）。2024。 PMID:38675782 Free PMC article。
Vaccination and its impact on healthcare utilization in two groups of vaccinated and unvaccinated patients with COVID-19:A cross-sectional study in Iran between2021and2022。
Kharazmi E，Bayati M，Majidpour Azad Shirazi A。 Kharazmi E，et al。 Health Sci Rep.2024 Feb23；7（2）：e1914。doi:10.1002/hsr2.1914。eCollection2024Feb。 Health Sci Rep.2024。 PMID:38405172 Free PMC article。
Transchromosomic bovine-derived anti-SARS-CoV-2polyclonal human antibodies protects hACE2transgenic hamsters against multiple variants。
Gilliland T，Dunn M，Liu Y，Alcorn MDH，Terada Y，Vasilatos S，Lundy J，Li R，Nambulli S，Larson D，Duprex P，Wu H，Luke T，Bausch C，Egland K，Sullivan E，Wang Z，Klimstra WB。 Gilliland T，et al。 iScience。2023 Aug29；26（10）：107764。doi:10.1016/j.isci.2023.107764。eCollection2023Oct20。 iScience。2023。 PMID:37736038 Free PMC article。
utation Analysis of SARS-CoV-2 Variants Isolated from Symptomatic Cases from Andhra Pradesh，India。
Nagaraja M，Sireesha K，Srikar A，Sudheer Kumar K，Mohan A，Vengamma B，Tirumala C，Verma A，Kalawat U。 Nagaraja M，et al。 Viruses。2023 Jul29；15（8）：1656。doi:10.3390/v15081656。 Viruses。2023。 PMID:37631999 Free PMC article。
The End or a New Era of Development of SARS-CoV-2 Virus:Genetic Variants Responsible for Severe COVID-19and Clinical Effficacy of the Most Commonly Used Vaccines in Clinical Practice。
iteva D，Kitanova M，Batselova H，Lazova S，Chervenkov L，Peshevsa-Sekulovska M，Sekulovski M，Gulinac M，Vasilev GV，Tomov L，Velikova T。 iteva D，et al。 Vaccines（Basel）。2023 Jun30；11（7）：1181。doi:10.3390/vaccines11071181。 Vaccines（Basel）。2023。 PMID:37514997 Free PMC article。 Review。

See all“Cited by”articles

参考，参考

1. Denison M.R.，Graham R.L.，Donaldson E.F.，Eckerle L.D.，Baric R.S.Coronaviruses:An RNA Proofreading Machine Regulates Replication Fidelity and Diversity。RNA Biol。2011；8:270–279。doi:10.4161/rna.8.2.15013。-是的DOI-是的PMC-是的PubMed
1. Korber B.，Fischer W.M.，Gnakaran S.，Yoon H.，Theiler J.，Abfalterer W.，Hengartner N.，Giorgi E.E.，Bhattacharya T.，Foley B.，et al.Tracking Changes in SARS-CoV-2 Spike:Evidence That D614G Increases Infectivity of the COVID-19Virus。Cell。2020；182:812-827.e19。doi:10.1016/j.cell.2020.06.043。-是的DOI-是的PMC-是的PubMed
1. Hou Y.J.，Chiba S.，Halfmann P.，Ehre C.，Kuroda M.，Dinnon K.H.，Leist S.R.，Schäfer A.，Nakajima N.，Takahashi K.，et al.SARS-CoV-2D614G Variant Exhibits Efficient Replication Ex Vivo and Transssimion In Vivo。Science。2020；370 doi:10.1126/science.abe8499。-是的DOI-是的PMC-是的PubMed
1. Baden L.R.，El Sahly H.M.，Essink B.，Kotloff K.，Frey S.，Novak R.，Diemert D.，Spector S.A.，Rouphael N.，Creech C.B.，et al.Efficacy and Safety of the MRNA-1273 SARS-COV-2Vaccine。N.Engl。J.Med.2021；384:403-416。doi:10.01056/NEJMoa2035389。-是的DOI-是的PMC-是的PubMed
1. Polack F.P.，Thomas S.J.，Kitchin N.，Absalon J.，Gurtman A.，Lockhart S.，Perez J.L.，Pérez Marc G.，Moreira E.D.，Zerbini C.，et al.Safety and Efficacy of the BNT162b2MRNA Covid-19Vaccine。N.Engl。J.Med.2020；383:2603–2615。doi:10.01056/NEJMoa2034577。-是的DOI-是的PMC-是的PubMed

Publication types

动作，动作

Grants and funding

CF01-0008/“la Caixa”Foundation

LinkOut-more resources

全文本源
Other Literature Sources
- 通道电路
- scite Smart Citations
iscellaneous
- NCI CPTAC Assay Portal

[1] Denison M.R.，Graham R.L.，Donaldson E.F.，Eckerle L.D.，Baric R.S.Coronaviruses:An RNA Proofreading Machine Regulates Replication Fidelity and Diversity。RNA Biol。2011；8:270–279。doi:10.4161/rna.8.2.15013。-是的DOI-是的PMC-是的PubMed

[2] Denison M.R.，Graham R.L.，Donaldson E.F.，Eckerle L.D.，Baric R.S.Coronaviruses:An RNA Proofreading Machine Regulates Replication Fidelity and Diversity。RNA Biol。2011；8:270–279。doi:10.4161/rna.8.2.15013。-是的DOI-是的PMC-是的PubMed

[3] Korber B.，Fischer W.M.，Gnakaran S.，Yoon H.，Theiler J.，Abfalterer W.，Hengartner N.，Giorgi E.E.，Bhattacharya T.，Foley B.，et al.Tracking Changes in SARS-CoV-2 Spike:Evidence That D614G Increases Infectivity of the COVID-19Virus。Cell。2020；182:812-827.e19。doi:10.1016/j.cell.2020.06.043。-是的DOI-是的PMC-是的PubMed

[4] Korber B.，Fischer W.M.，Gnakaran S.，Yoon H.，Theiler J.，Abfalterer W.，Hengartner N.，Giorgi E.E.，Bhattacharya T.，Foley B.，et al.Tracking Changes in SARS-CoV-2 Spike:Evidence That D614G Increases Infectivity of the COVID-19Virus。Cell。2020；182:812-827.e19。doi:10.1016/j.cell.2020.06.043。-是的DOI-是的PMC-是的PubMed

[5] Hou Y.J.，Chiba S.，Halfmann P.，Ehre C.，Kuroda M.，Dinnon K.H.，Leist S.R.，Schäfer A.，Nakajima N.，Takahashi K.，et al.SARS-CoV-2D614G Variant Exhibits Efficient Replication Ex Vivo and Transssimion In Vivo。Science。2020；370 doi:10.1126/science.abe8499。-是的DOI-是的PMC-是的PubMed

[6] Hou Y.J.，Chiba S.，Halfmann P.，Ehre C.，Kuroda M.，Dinnon K.H.，Leist S.R.，Schäfer A.，Nakajima N.，Takahashi K.，et al.SARS-CoV-2D614G Variant Exhibits Efficient Replication Ex Vivo and Transssimion In Vivo。Science。2020；370 doi:10.1126/science.abe8499。-是的DOI-是的PMC-是的PubMed

[7] Baden L.R.，El Sahly H.M.，Essink B.，Kotloff K.，Frey S.，Novak R.，Diemert D.，Spector S.A.，Rouphael N.，Creech C.B.，et al.Efficacy and Safety of the MRNA-1273 SARS-COV-2Vaccine。N.Engl。J.Med.2021；384:403-416。doi:10.01056/NEJMoa2035389。-是的DOI-是的PMC-是的PubMed

[8] Baden L.R.，El Sahly H.M.，Essink B.，Kotloff K.，Frey S.，Novak R.，Diemert D.，Spector S.A.，Rouphael N.，Creech C.B.，et al.Efficacy and Safety of the MRNA-1273 SARS-COV-2Vaccine。N.Engl。J.Med.2021；384:403-416。doi:10.01056/NEJMoa2035389。-是的DOI-是的PMC-是的PubMed

[9] Polack F.P.，Thomas S.J.，Kitchin N.，Absalon J.，Gurtman A.，Lockhart S.，Perez J.L.，Pérez Marc G.，Moreira E.D.，Zerbini C.，et al.Safety and Efficacy of the BNT162b2MRNA Covid-19Vaccine。N.Engl。J.Med.2020；383:2603–2615。doi:10.01056/NEJMoa2034577。-是的DOI-是的PMC-是的PubMed

[10] Polack F.P.，Thomas S.J.，Kitchin N.，Absalon J.，Gurtman A.，Lockhart S.，Perez J.L.，Pérez Marc G.，Moreira E.D.，Zerbini C.，et al.Safety and Efficacy of the BNT162b2MRNA Covid-19Vaccine。N.Engl。J.Med.2020；383:2603–2615。doi:10.01056/NEJMoa2034577。-是的DOI-是的PMC-是的PubMed

保存顺序文件

Email citation

添加到Collections

添加到我的Bibliography

Your saved search

创建文件专用分类管理软件

Your RSS Feed

Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19

空气净化

Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19

Authors

空气净化

Abstract

整体安装

Similar articles

Cited by

参考，参考

Publication types

Grants and funding

LinkOut-more resources

全文本源

Other Literature Sources

iscellaneous